目的 探讨参乌益肾片联合复方α酮酸片治疗慢性肾衰竭的临床疗效。方法 选取2020年4月-2021年3月在商丘市第一人民医院就诊的90例慢性肾衰竭患者,按随机数字表法分为对照组和治疗组,每组各45例。对照组口服复方α酮酸片,4片/次,3次/d。治疗组在对照组基础上口服参乌益肾片,4片/次,3次/d。两组连续治疗6个月。观察两组临床疗效,比较两组肾功能和血清炎症因子水平。结果 治疗后,治疗组的总有效率为95.56%,明显高于对照组的总有效率80.00%,差异有统计学意义(P<0.05)。治疗后,两组的胱抑素C(Cys-C)、β₂-微球蛋白(β₂-MG)低于治疗前,肾小球滤过率(eGFR)高于治疗前(P<0.05);治疗组的Cys-C、β₂-MG低于对照组,eGFR高于对照组,差异有统计学意义(P<0.05)。治疗后,两组的血清基质金属蛋白酶-9(MMP-9)、单核细胞趋化蛋白-1(MCP-1)、中性粒细胞相关载脂蛋白(NGAL)水平低于治疗前(P<0.05),且治疗组的血清MMP-9、MCP-1、NGAL水平明显低于对照组,差异有统计学意义(P<0.05)。结论 参乌益肾片联合复方α酮酸片治疗慢性肾衰竭的疗效确切,可改善肾功能,降低肾脏炎症水平,安全性良好。

Objective To investigate the clinical effect of Shenwu Yishen Tablets combined with Compound α-Ketoacid Tablets in treatment of chronic renal failure. Methods Patients (90 cases) with chronic renal failure in Shangqiu First People’s Hospital from April 2020 to March 2021 were divided into control and treatment groups according to random number table method, and each group had 45 cases. Patients in the control group were po administered with Compound α-Ketoacid Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Shenwu Yishen Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and the renal function and the inflammatory factor in two groups were compared. Results After treatment, the total effective rate in the treatment group was 95.56%, which was significantly higher than that in the control group (80.00%), with statistically significant difference (P＜0.05). After treatment, the levels of Cys-C and β₂-MG of two groups were decreased, but the levels of eGFR of two groups were increased (P＜0.05).The levels of Cys-C and β₂-MG in the treatment group were lower than those in the control group, but the levels of eGFR in the treatment group were higher than those in the control group, with a statistically significant difference (P＜0.05). After treatment, the serum levels of MMP-9, MCP-1, and NGAL in two groups were lower than those before treatment (P＜0.05), and the serum levels of MMP-9, MCP-1, and NGAL in the treatment group were significantly lower than those in the control group (P＜0.05). Conclusion Shenwu Yishen Tablets combined with Compound α-Ketoacid Tablets has clinical curative effect in treatment of chronic renal failure, can improve renal function, reduce renal inflammation, with good safety.

R986

河南省医学科技攻关计划联合共建项目(LHGJ20191505)